📊 PRAX Key Takeaways
Is Praxis Precision Medicines, Inc. (PRAX) a Good Investment?
Praxis is a pre-revenue biotech company with zero product sales and annual operating losses of $326.2M against just $357.3M in cash reserves, yielding approximately 1.4 years of runway at current burn rates. While the balance sheet is fortress-like with zero debt and $878.1M in equity, the company faces critical execution risk dependent on pipeline success with no near-term revenue visibility. The modest improvement in net losses YoY is insufficient to offset fundamental insolvency trends unless dramatic cost reductions or financing occur.
Why Buy Praxis Precision Medicines, Inc. Stock? PRAX Key Strengths
- Pristine balance sheet with $878.1M stockholders equity and zero debt
- Strong liquidity position with 10.22x current ratio and $357.3M cash
- Declining loss trajectory (net income improved 65.9% YoY, losses reduced from -$303.3M)
PRAX Stock Risks: Praxis Precision Medicines, Inc. Investment Risks
- Pre-revenue stage with zero product sales despite established operations
- Unsustainable cash burn of $249.1M annually against finite cash reserves
- Limited 1.4-year cash runway at current operating burn rate without additional financing
- Complete dependence on pipeline drug development success with binary outcome risk
- Minimal insider confidence signaled by only 2 Form 4 filings in 90 days
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway
- Clinical trial progress and FDA milestones for key pipeline candidates
- Burn rate trajectory and management commentary on path to positive cash flow
Praxis Precision Medicines, Inc. (PRAX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.22x current ratio provides a solid financial cushion.
PRAX Profit Margin, ROE & Profitability Analysis
PRAX vs Healthcare Sector: How Praxis Precision Medicines, Inc. Compares
How Praxis Precision Medicines, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Praxis Precision Medicines, Inc. Stock Overvalued? PRAX Valuation Analysis 2026
Based on fundamental analysis, Praxis Precision Medicines, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Praxis Precision Medicines, Inc. Balance Sheet: PRAX Debt, Cash & Liquidity
PRAX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Praxis Precision Medicines, Inc.'s revenue has grown significantly by 250% over the 5-year period, indicating strong business expansion. The most recent EPS of $-18.69 indicates the company is currently unprofitable.
PRAX Revenue Growth, EPS Growth & YoY Performance
PRAX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$32.7M | $-2.75 |
| Q2 2025 | N/A | -$32.7M | $-1.74 |
| Q1 2025 | N/A | -$39.6M | $-2.84 |
| Q3 2024 | $302.0K | -$24.6M | $-2.72 |
| Q2 2024 | $357.0K | -$32.7M | $-1.74 |
| Q1 2024 | $431.0K | -$37.5M | $-2.84 |
| Q3 2023 | N/A | -$24.6M | $-0.18 |
| Q2 2023 | N/A | -$34.3M | $-0.49 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Praxis Precision Medicines, Inc. Dividends, Buybacks & Capital Allocation
PRAX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Praxis Precision Medicines, Inc. (CIK: 0001689548)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRAX
What is the AI rating for PRAX?
Praxis Precision Medicines, Inc. (PRAX) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRAX's key strengths?
Claude: Pristine balance sheet with $878.1M stockholders equity and zero debt. Strong liquidity position with 10.22x current ratio and $357.3M cash.
What are the risks of investing in PRAX?
Claude: Pre-revenue stage with zero product sales despite established operations. Unsustainable cash burn of $249.1M annually against finite cash reserves.
What is PRAX's revenue and growth?
Praxis Precision Medicines, Inc. reported revenue of $0.0.
Does PRAX pay dividends?
Praxis Precision Medicines, Inc. does not currently pay dividends.
Where can I find PRAX SEC filings?
Official SEC filings for Praxis Precision Medicines, Inc. (CIK: 0001689548) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRAX's EPS?
Praxis Precision Medicines, Inc. has a diluted EPS of $-13.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRAX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Praxis Precision Medicines, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRAX stock overvalued or undervalued?
Valuation metrics for PRAX: ROE of -34.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRAX stock in 2026?
Our dual AI analysis gives Praxis Precision Medicines, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRAX's free cash flow?
Praxis Precision Medicines, Inc.'s operating cash flow is $-249.1M, with capital expenditures of $56.0K.
How does PRAX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -34.5% (avg: 15%), current ratio 10.22 (avg: 2).